ABSTRACT
This chapter presents Akili's experiences and lessons learned from the development of a first-in-class digital therapeutic. Akili Interactive Labs (Akili) was founded in 2011 by Eddie Martucci, Ph.D, Matthew Omernick, and Adam Gazzaley, MD, Ph.D. It is a digital therapeutic company combining scientific and clinical rigor with the ingenuity of the tech industry to reinvent medicine. Akili develops technologies that target cognitive impairments across different medical disorders. Attention is a fundamental cognitive function and can be thought of as a sub-process of cognition that modulates information processing in a goal-consistent manner via attentional control. At the beginning of each new level, the user is assessed while performing Targeting and Navigation in isolation and simultaneously. Akili strives to develop technologies that are both clinically and regulatory validated.
